Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tucidinostat (Chidamide) is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $58 | In Stock | |
10 mg | $92 | In Stock | |
25 mg | $171 | In Stock | |
50 mg | $277 | In Stock | |
100 mg | $443 | In Stock | |
200 mg | $621 | In Stock | |
500 mg | $925 | In Stock | |
1 mL x 10 mM (in DMSO) | $58 | In Stock |
Description | Tucidinostat (Chidamide) is an effective and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC50s of 95, 160, 67 and 78 nM, less active on HDAC8/11 (IC50: 733/432 nM), and shows no effect on HDAC4/5/6/7/9. |
Targets&IC50 | HDAC1:95 nM (Cell-free), HDAC10:78 nM (Cell-free), HDAC3:67 nM (Cell-free), HDAC2:160 nM (Cell-free) |
In vitro | Tucidinostat shows potent antitumor activity and inhibits several human-derived tumour cell lines, such as HL-60, U2OS, LNCaP with GI50s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL)[1]. |
In vivo | Tucidinostat, administered orally at doses ranging from 12.5 to 50 mg/kg, effectively and dose-dependently decreases tumor size and weight in mice afflicted with various carcinomas including HCT-8 colorectal, A549 lung, BEL-7402 liver, and MCF-7 breast, without any significant loss in body weight[1]. |
Alias | HBI-8000, CS 055, Chidamide |
Molecular Weight | 390.41 |
Formula | C22H19FN4O2 |
Cas No. | 1616493-44-7 |
Smiles | Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)\C=C\c2cccnc2)cc1 |
Relative Density. | 1.336 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | H2O: Insoluble DMSO: 60 mg/mL (153.68 mM), Sonication is recommended. ![]() Ethanol: 1 mg/mL (2.56 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 6 mg/mL (15.37 mM), suspension.In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.